Transglutaminase inhibition reduces fibrosis and preserves function in experimental chronic kidney disease.
Johnson
Tim S
TS
Melvyn Round Kidney Research Laboratories, Sheffield Kidney Institute, Northern General Hospital, University of Sheffield, Sheffield, UK. t.johnson@sheffield.ac.uk
Fisher
Marie
M
Haylor
John L
JL
Hau
Zoe
Z
Skill
N James
NJ
Jones
Richard
R
Saint
Robert
R
Coutts
Ian
I
Vickers
Melissa E
ME
El Nahas
A Meguid
AM
Griffin
Martin
M
D000818:Animals; D001835:Body Weight; D002908:Chronic Disease; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005355:Fibrosis / Q000473:pathology*; D005923:Glomerulosclerosis, Focal Segmental / Q000378:metabolism; D006801:Humans; D007668:Kidney / Q000378:metabolism / Q000473:pathology; D007674:Kidney Diseases / Q000473:pathology*; D007684:Kidney Tubules / Q000378:metabolism; D008297:Male; D008954:Models, Biological; D009929:Organ Size; D051381:Rats; D017208:Rats, Wistar; D011503:Transglutaminases / Q000037:antagonists & inhibitors*
D004791:Enzyme Inhibitors; D011503:Transglutaminases